{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 33,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 21,
  "notes": "The slide uses a line chart to demonstrate the efficacy of different dosages of COMP360 over 12 weeks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/16",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.26,
        "x": 0.65,
        "y": 0.37
      },
      "kind": "callout",
      "text": "Primary Endpoint: Difference vs 1mg at Week 3: 25mg Diff = -6.6, p value = <0.001; 10mg Diff = -2.5, p value = 0.184",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca470642-9a38-4ab8-9abf-819012d19d57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.38,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Line chart showing MADRS score change over 12 weeks for 25mg, 10mg, and 1mg doses.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f557031-0615-463a-9b8a-21bbc7cbe677",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.3,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "list",
      "text": "OWNERSHIP: 22.5% | PRODUCT: Oral Psilocybin (COMP360) | PHARMACOLOGY: 5-HT2A-R agonist | PRODUCT FEATURES: Rapid onset, potential for sustained efficacy | INDICATIONS: TRD, Anorexia, PTSD | STATUS: Phase 3 (TRD) | IP: Proprietary formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85603fa3-5d4b-426d-ae12-4906878e435a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021, as amended. Note: MADRS = Montgomery-Åsberg Depression Rating Scale.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3923a733-bf39-43c9-889b-2d68adc6241b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ae990d8-fb30-413c-aad6-517c1bd71de5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96690ec6-6305-4670-a328-7db0358ebdf6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8f5a575a-6ced-4f97-a957-76a471eb55b9",
      "evidence": "The deck emphasizes the unmet need for effective treatments in depression, highlighting the potential consequences of inaction.",
      "position": 0,
      "objective": "Highlight the urgent need for innovation in depression treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}